Skip to main content
. 2011 Jul 5;2011(7):CD008305. doi: 10.1002/14651858.CD008305.pub2
Incremental cost‐effectiveness ratio
Study Group TC TG LDL‐C HDL‐C
Xuezhikang versus pravastatin
Wang 2003 Xuezhikang group 100 100 100 100
Wang 2003 Pravastatin group 135.75 338.84 141.56 93.01